You cannot select more than 25 topics
Topics must start with a letter or number, can include dashes ('-') and can be up to 35 characters long.
368 lines
11 KiB
TeX
368 lines
11 KiB
TeX
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
|
|
% Beamer Presentation
|
|
% LaTeX Template
|
|
% Version 1.0 (10/11/12)
|
|
%
|
|
% This template has been downloaded from:
|
|
% http://www.LaTeXTemplates.com
|
|
%
|
|
% License:
|
|
% CC BY-NC-SA 3.0 (http://creativecommons.org/licenses/by-nc-sa/3.0/)
|
|
%
|
|
% Changed theme to WSU by William King
|
|
%
|
|
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
|
|
|
|
%----------------------------------------------------------------------------------------
|
|
% PACKAGES AND THEMES
|
|
%----------------------------------------------------------------------------------------
|
|
|
|
\documentclass[xcolor=dvipsnames,aspectratio=169]{beamer}
|
|
|
|
|
|
%Import Preamble bits
|
|
\input{../assets/preambles/FormattingPreamble.tex}
|
|
\input{../assets/preambles/TikzitPreamble.tex}
|
|
\input{../assets/preambles/MathPreamble.tex}
|
|
\input{../assets/preambles/BibPreamble.tex}
|
|
\input{../assets/preambles/GeneralPreamble.tex}
|
|
|
|
|
|
|
|
|
|
|
|
%----------------------------------------------------------------------------------------
|
|
% TITLE PAGE
|
|
%----------------------------------------------------------------------------------------
|
|
|
|
\title[Clinical Trials]{Pharmaceutial competitors and their effect on clinical trial completion}
|
|
|
|
\author{Will King} % Your name
|
|
\institute[WSU] % Your institution as it will appear on the bottom of every slide, may be shorthand to save space
|
|
{
|
|
Washington State University \\ % Your institution for the title page
|
|
\medskip
|
|
\textit{william.f.king@wsu.edu} % Your email address
|
|
}
|
|
\date{\today} % Date, can be changed to a custom date
|
|
|
|
|
|
|
|
|
|
|
|
\begin{document}
|
|
\begin{frame}
|
|
\titlepage % Print the title page as the first slide
|
|
\end{frame}
|
|
|
|
|
|
%-------------------------------
|
|
\begin{frame}
|
|
\frametitle{Introduction}
|
|
|
|
\end{frame}
|
|
%-------------------------------
|
|
\begin{frame}[allowframebreaks] %Allow frame breaks
|
|
\frametitle{Overview} % Table of contents slide, comment this out to remove it
|
|
\tableofcontents
|
|
\end{frame}
|
|
%-------------------------------
|
|
|
|
%-------------------------------------------------------------------------------------
|
|
%%%%%%%%%%%%%%%%%%%% Introduction and Background %%%%%%%%%%%%%%%%%%%%%%%%
|
|
\section{Background}
|
|
% TOC
|
|
% - Background on drug process
|
|
% - Literature on clinical trials
|
|
% - My questions
|
|
%-------------------------------------------------------------------------------------
|
|
|
|
%-------------------------------
|
|
\begin{frame}
|
|
\frametitle{Clinical Trials and Drug develoment}
|
|
% add info about trials
|
|
% - Requirements (pre registered design [2007], updated "regularly" on clinicaltrials.gov)
|
|
% - Phases (1,2,3,4, mixed)
|
|
% - Safety and Ethicas (oversight boards, restrictions on payments)
|
|
% - Approval processes (biologics vs small-molecule)
|
|
% add info about drugs
|
|
|
|
The FDA requires clinical trials before approving new drug compounds
|
|
\begin{itemize}
|
|
\item Pre-registered design
|
|
\item Updated regularly on clinicaltrials.gov
|
|
\item Often requires an oversight board.
|
|
\item Goal is to prove efficacy and safety of a compound/dosage/route.
|
|
\item A new drug candidate (NDC) must complete 3 phases of clinical trials before approval.
|
|
\item Phases are reviewed with FDA.
|
|
\item Not all clinical trials are for new drugs.
|
|
\end{itemize}
|
|
\end{frame}
|
|
%-----------------------------
|
|
\begin{frame}
|
|
\frametitle{Literature}
|
|
\begin{itemize}
|
|
\item Ekaterina
|
|
\item Adams
|
|
\item
|
|
\end{itemize}
|
|
|
|
\end{frame}
|
|
%-----------------------------
|
|
\begin{frame}
|
|
\frametitle{Questions of Interest}
|
|
|
|
\begin{itemize}
|
|
\item How do the competitors on the market affect clinical trial completion?
|
|
\item How is this effect moderated by the enrollment of participants?
|
|
\end{itemize}
|
|
\end{frame}
|
|
%-------------------------------
|
|
\begin{frame}
|
|
\frametitle{Audience Questions}
|
|
|
|
\center{What can I clarify?}
|
|
\end{frame}
|
|
%-------------------------------
|
|
%-------------------------------------------------------------------------------------
|
|
%%%%%%%%%%%%%%%%%%%% Causality and Data %%%%%%%%%%%%%%%%%%%%%%%%
|
|
\section{Causal Story and Data}
|
|
% TOC
|
|
% - Causal Story (no subsection)
|
|
% - Clinical trials: targets specific drug/condition combination.
|
|
% - Enrollment process: patients counsel with providers
|
|
% - Trials terminate if unsafe, ineffective, unprofitable, or cannot enroll patients
|
|
% - Ethical concerns exist throughout.
|
|
% - This is complicated by the fact that the experiment reveals information over time.
|
|
% - Formalization
|
|
% - Data Sources
|
|
%-------------------------------------------------------------------------------------
|
|
|
|
%-------------------------------
|
|
\begin{frame}[shrink=10] %evil option is helpful here.
|
|
\frametitle{How do clinical trials proceed?}
|
|
\begin{columns}[T]
|
|
\begin{column}{0.5\textwidth}
|
|
What does a complete trial look like.
|
|
\begin{enumerate}
|
|
\item Study sponsor comes up with design
|
|
\item Apply for NCT ID from ClinicalTrials.gov
|
|
\item Begin enrolling participants
|
|
\item Update ClinicalTrials.gov to recruit
|
|
\item Close Enrollment
|
|
\item Update ClinicalTrials.gov as not recruiting*
|
|
\item Reach primary objectives
|
|
\item Update ClinicalTrials.gov as complete
|
|
\item Reach secondary objectives
|
|
\item Update ClinicalTrials.gov with more information
|
|
\end{enumerate}
|
|
\end{column}
|
|
\begin{column}{0.5\textwidth}
|
|
What does an incomplete trial look like?
|
|
\begin{enumerate}
|
|
\item Study sponsor comes up with design
|
|
\item Apply for NCT ID from ClinicalTrials.gov
|
|
\item Begin enrolling participants
|
|
\item Update ClinicalTrials.gov to advertise
|
|
\item Run into issues:
|
|
\begin{itemize}
|
|
\item Safety
|
|
\item Efficacy
|
|
\item Profitability
|
|
\item Feasiblity (enrollment, PI leaves, etc.)
|
|
\end{itemize}
|
|
\item Close Enrollment*
|
|
\item Decide to terminate clinical trial.
|
|
\item Update ClinicalTrials.gov as terminated.
|
|
\end{enumerate}
|
|
\end{column}
|
|
\end{columns}
|
|
\end{frame}
|
|
%-------------------------------
|
|
\begin{frame}
|
|
\frametitle{ClinicalTrials.gov}
|
|
Thus ClinicalTrials.gov becomes an (append only) repository of
|
|
the ``current'' status of clincal trials.
|
|
|
|
|
|
As it is designed to help faciltate enrollment in clinical trials,
|
|
the record includes important information such as
|
|
|
|
\begin{itemize}
|
|
\item drugs
|
|
\item study arms
|
|
\item conditions
|
|
\item expected and final enrollment figures
|
|
\item current status
|
|
\end{itemize}
|
|
|
|
ClinicalTrials.gov also reports the ``history'' from previous
|
|
updates.
|
|
\end{frame}
|
|
|
|
%-------------------------------
|
|
\begin{frame}
|
|
\frametitle{Questions?}
|
|
|
|
\end{frame}
|
|
%-------------------------------
|
|
%--------------------------------
|
|
%%%%%%%%%%%%%%%%%%%% Causal Formalization
|
|
\subsection{Formalization}
|
|
% - Introduce basic triangle
|
|
% - discuss total vs direct effects
|
|
% -
|
|
% - Add confounders and controls
|
|
% - Introduce backdoor criterion
|
|
%--------------------------------
|
|
|
|
|
|
%-------------------------------
|
|
\begin{frame}
|
|
\frametitle{Questions?}
|
|
|
|
\end{frame}
|
|
%-------------------------------
|
|
%--------------------------------
|
|
%%%%%%%%%%%%%%%%%%%% Data sources
|
|
\subsection{Data Sources}
|
|
% TOC
|
|
% - Main Data Sources
|
|
% - ClinicalTrials.gov and AACT
|
|
% - IHME Burden of Disease
|
|
% - Marketing Data
|
|
% - MeSH, RxNorm/RxNav
|
|
% - How did I Link Data Sources
|
|
% - Data Sizes
|
|
%--------------------------------
|
|
|
|
%-------------------------------
|
|
\begin{frame}
|
|
\frametitle{Questions?}
|
|
|
|
\end{frame}
|
|
%-------------------------------
|
|
%-------------------------------------------------------------------------------------
|
|
%%%%%%%%%%%%%%%%%%%% Analysis %%%%%%%%%%%%%%%%%%%%%%%%
|
|
\section{Analysis}
|
|
% TOC
|
|
% - Review questions and datasets to use for each
|
|
% -
|
|
% -
|
|
%-------------------------------------------------------------------------------------
|
|
|
|
%-------------------------------
|
|
\begin{frame}
|
|
\frametitle{Questions?}
|
|
|
|
\end{frame}
|
|
%--------------------------------
|
|
%%%%%%%%%%%%%%%%%%%% Econometric Model
|
|
\subsection{Econometric Model}
|
|
% - Present model per effect
|
|
% -
|
|
% -
|
|
%--------------------------------
|
|
|
|
%-------------------------------
|
|
\begin{frame}
|
|
\frametitle{Questions?}
|
|
|
|
\end{frame}
|
|
%--------------------------------
|
|
%%%%%%%%%%%%%%%%%%%% Results
|
|
\subsection{Results}
|
|
%--------------------------------
|
|
%--------------------------------
|
|
\subsubsection{Total Effect}
|
|
% - Review Parameter Values
|
|
% - hyperparameters
|
|
% - Table of MLE
|
|
% - Distributions
|
|
% - betas
|
|
% - Table of MLE
|
|
% - Distributions
|
|
% - Review Posterior Prediction for interventions
|
|
%--------------------------------
|
|
%-------------------------------
|
|
\begin{frame}
|
|
\frametitle{Questions?}
|
|
|
|
\end{frame}
|
|
%-------------------------------
|
|
%--------------------------------
|
|
\subsubsection{Direct Effects}
|
|
% - Review Parameter Values
|
|
% - hyperparameters
|
|
% - Table of MLE
|
|
% - Distributions
|
|
% - betas
|
|
% - Table of MLE
|
|
% - Distributions
|
|
% - Review Posterior Prediction for interventions
|
|
%--------------------------------
|
|
|
|
%-------------------------------
|
|
\begin{frame}
|
|
\frametitle{Questions?}
|
|
|
|
\end{frame}
|
|
%-------------------------------
|
|
%-------------------------------------------------------------------------------------
|
|
%%%%%%%%%%%%%%%%%%%% Conclusion %%%%%%%%%%%%%%%%%%%%%%%%
|
|
\section{Conclusion}
|
|
%-------------------------------------------------------------------------------------
|
|
|
|
%-------------------------------
|
|
\begin{frame}
|
|
\frametitle{Final Questions}
|
|
|
|
\center{\huge{Time is yours to ask any remaining questions.}}
|
|
\end{frame}
|
|
%-------------------------------------------------------------------------------------
|
|
%%%%%%%%%%%%%%%%%%%% Appendicies %%%%%%%%%%%%%%%%%%%%%%%%
|
|
\section{Appendices}
|
|
%-------------------------------------------------------------------------------------
|
|
|
|
%-------------------------------
|
|
\begin{frame}
|
|
\frametitle{Equilibrium in the Money Market}
|
|
Interest rates are the price of money, so we need to compare
|
|
interest rates to the quantity of money demanded.
|
|
|
|
|
|
\begin{figure}
|
|
% \tikzfig{../Assets/tikzit/}
|
|
\label{FIG:costs}
|
|
\caption{Money Market Equilibrium}
|
|
\end{figure}
|
|
\end{frame}
|
|
%-------------------------------
|
|
\end{document}
|
|
%=========================================
|
|
%\begin{frame}
|
|
% \frametitle{MarginalRevenue}
|
|
% \begin{figure}
|
|
% \tikzfig{../Assets/owned/ch8_MarginalRevenue}
|
|
% \includegraphics[height=\textheight]{../Assets/copyrighted/KrugmanObsterfeldMeliz_fig8-7.jpg}
|
|
% \label{FIG:costs}
|
|
% \caption{Average Cost Curve as firms enter.}
|
|
% \end{figure}
|
|
%\end{frame}
|
|
%-------------------------------
|
|
%\begin{frame}
|
|
% \frametitle{Columns}
|
|
% \begin{columns}
|
|
% \begin{column}{0.5\textwidth}
|
|
% \end{column}
|
|
% \begin{column}{0.5\textwidth}
|
|
% \begin{figure}
|
|
% \tikzfig{../Assets/owned/ch7_EstablishedAdvantageExample2}
|
|
% \label{FIG:costs}
|
|
% \caption{Setting the Stage}
|
|
% \end{figure}
|
|
% \end{column}
|
|
% \end{columns}
|
|
%\end{frame}
|
|
% %---------------------------------------------------------------
|